Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ipratropium bromide
Drug ID BADD_D01192
Description Ipratropium is a quaternary ammonium derivative of [atropine][A176957] that acts as an anticholinergic agent.[A176939] It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption.[A176957] Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol] was approved in 1996.[L5894, L5891]
Indications and Usage For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Marketing Status Prescription; Discontinued
ATC Code R01AX03; R03BB01
DrugBank ID DB00332
KEGG ID D02212
MeSH ID D009241
PubChem ID 657308
TTD Drug ID D0S0AS
NDC Product Code 60687-394; 0591-3798; 53104-7704; 0597-0087; 60505-0826; 50090-0961; 76204-100; 53002-8410; 0378-7970; 55154-4351; 15308-1001; 16714-526; 12714-049; 0487-9801; 50090-0668; 68071-1737; 49452-3791; 66412-0753; 24208-398; 51552-1500; 24208-399; 50090-4185; 63187-188; 65862-905; 58032-0100; 70518-2874; 43235-0013; 52221-108; 59349-0013; 16714-527; 0054-0045; 0054-0046; 47335-706; 43898-0102; 70518-1070; 60505-0827
Synonyms Ipratropium | (endo,syn)-(+-)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane | N-Isopropylatropine | N Isopropylatropine | Atrovent | Ipratropium Bromide Anhydrous | Ipratropium Bromide, (endo,anti)-Isomer | Sch-1178 | Sch 1178 | Sch1178 | Ipratropium Bromide Monohydrate | Ipratropium Bromide, endo-Isomer | Itrop | Sch-1000 | Sch 1000 | Sch1000 | Ipratropium Bromide | Ipratropium Bromide, (exo,syn)-Isomer
Chemical Information
Molecular Formula C20H30BrNO3
CAS Registry Number 22254-24-6
SMILES CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Accommodation disorder06.02.04.001--Not Available
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Angioedema23.04.01.001; 10.01.05.009--Not Available
Angle closure glaucoma06.03.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Atrial fibrillation02.03.03.002--
Bronchospasm22.03.01.004; 10.01.03.012--
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Corneal oedema06.04.02.001--Not Available
Cough22.02.03.001--
Diarrhoea07.02.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry mouth07.06.01.002--
Dry throat22.02.05.004; 07.06.01.005--Not Available
Dysgeusia17.02.07.003; 07.14.03.001--
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.004--
Epistaxis24.07.01.005; 22.04.03.001--
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Glaucoma06.03.01.002--
Halo vision06.02.06.003--Not Available
Headache17.14.01.001--
Heart rate increased13.14.04.002--Not Available
Hypersensitivity10.01.03.003--
Intestinal obstruction07.13.01.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
The 1th Page    1 2 3    Next   Last    Total 3 Pages